HUTCHMED (China) (HMDCF) Non-Current Deferred Tax Liability (2014 - 2025)
HUTCHMED (China)'s (HMDCF) quarterly Non-Current Deferred Tax Liability came in at $255000.0 in Q4 2025, down 90.59% quarter-over-quarter from $2.7 million in Q4 2022.
Analysis
HUTCHMED (China) (HMDCF) Non-Current Deferred Tax Liability (2014 - 2025) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Non-Current Deferred Tax Liability for 10 consecutive years, with $255000.0 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $255000.0 in Q4 2025; TTM through Dec 2025 was $255000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $255000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was $255000.0 for Q4 2025 at HUTCHMED (China), down from $2.7 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $2.8 million in Q4 2021 and troughed at $255000.0 in Q4 2025.
- A 3-year average of $1.9 million and a median of $2.7 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
- Across the five-year window, Non-Current Deferred Tax Liability declined 22.07% in 2021 and fell 1.99% in 2022, its largest moves.
- Over 3 years, Non-Current Deferred Tax Liability stood at $2.8 million in 2021, then decreased by 1.99% to $2.7 million in 2022, then tumbled by 90.59% to $255000.0 in 2025.
- The last three Non-Current Deferred Tax Liability figures came in at $255000.0 (Q4 2025), $2.7 million (Q4 2022), and $2.8 million (Q4 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 255,000.00 |
| Dec 31, 2022 | 2.71 Mn |
| Dec 31, 2021 | 2.77 Mn |
| Dec 31, 2020 | 3.55 Mn |
| Dec 31, 2019 | 2.34 Mn |
| Dec 31, 2018 | 4.26 Mn |
| Jun 30, 2018 | 5.05 Mn |
| Dec 31, 2017 | 3.82 Mn |
| Jun 30, 2017 | 4.19 Mn |
| Dec 31, 2016 | 4.99 Mn |
| Jun 30, 2016 | 2.40 Mn |
| Dec 31, 2015 | 3.47 Mn |
| Dec 31, 2014 | 2.84 Mn |